Global News

Juno partners Memorial Sloan Kettering and Eureka Therapeutics

Tuesday, August 9, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, has entered into an exclusive license agreement with Memorial Sloan-Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.

[Read More]

Myriad to acquire Assurex Health

Thursday, August 4, 2016

Myriad Genetics, a leader in molecular diagnostics and personalized medicine, has signed a definitive agreement to acquire Assurex Health, a global leader in genetic testing for psychotropic medicine selection, for $225 million upfront with the potential for $185 million in additional performance-based milestones. Assurex generated revenue of more than $60 million and tested more than 150,000 patients in Myriad’s fiscal year 2016.

[Read More]

Fitbit hires Adam Pellegrini as VP of Digital Health

Thursday, August 4, 2016

Fitbit has announced that Adam Pellegrini will join the company as vice president of Digital Health, beginning September 6. Pellegrini will be responsible for leading Fitbit’s vision, strategies and programs to further drive the company’s integration into healthcare systems around the world. In this new role, Pellegrini will harness the power of Fitbit’s products, software and services to help create better clinical health outcomes while identifying new revenue opportunities for the company, building on the momentum Fitbit has had to date with disease management, insurance and wellness programs.

[Read More]

NIH begins testing investigational Zika vaccine in humans

Thursday, August 4, 2016

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. The early-stage study will evaluate the experimental vaccine’s safety and ability to generate an immune system response in participants. At least 80 healthy volunteers ages 18-35 years at three study sites in the U.S., including the NIH Clinical Center in Bethesda, Maryland, are expected to participate in the trial. Scientists at NIAID’s Vaccine Research Center (VRC) developed the investigational vaccine—called the NIAID Zika virus investigational DNA vaccine—earlier this year.

[Read More]

Curable CEO Dr. Lisa Boyette named a 2016 PharmaVOICE 100 honoree

Wednesday, August 3, 2016

Curable, a nonprofit research accelerator that applies engineering approaches to medicine to develop solutions for rare diseases, has announced that its chief executive officer Lisa Boyette, M.D., Ph.D., has been named a 2016 PharmaVOICE 100 honoree. The PharmaVOICE 100 is an annual list of inspirational and innovative individuals recognized for their positive contributions to the life-sciences industry.

[Read More]

Regeneron, Adicet Bio collaborate on immune cell therapeutics

Wednesday, August 3, 2016

Regeneron Pharmaceuticals and Adicet Bio have announced a collaboration and licensing agreement to develop next-generation engineered immune cell therapeutics. The companies plan to engineer immune cells with fully human chimeric antigen receptors (CARs) and T-cell receptors (TCRs) directed to disease-specific cell surface antigens in order to enable the precise engagement and killing of tumor cells. The collaboration is intended to generate multiple clinical product candidates for various hematological and solid tumor cancers.

[Read More]